ADC Therapeutics (ADCT) Revenue: 2019-2023
Historic Revenue for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to $14.5 million.
- ADC Therapeutics' Revenue fell 81.01% to $14.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $52.8 million, marking a year-over-year decrease of 62.29%. This contributed to the annual value of $209,908 for FY2022, which is 518.89% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Revenue is $14.5 million, which was down 24.84% from $19.3 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Revenue registered a high of $30.5 billion during Q3 2019, and its lowest value of -$77.1 billion during Q4 2019.
- Its 3-year average for Revenue is $18.6 million, with a median of $14.5 million in 2023.
- The largest annual percentage gain for ADC Therapeutics' Revenue in the last 5 years was 40,602.79% (2021), contrasted with its biggest fall of 7,917.70% (2021).
- ADC Therapeutics' Revenue (Quarterly) stood at -$77.1 billion in 2019, then slumped by 100.00% to $32,300 in 2020, then soared by 40,602.79% to $17,010 in 2021, then skyrocketed by 310.34% to $69,798 in 2022, then plummeted by 81.01% to $14.5 million in 2023.
- Its Revenue was $14.5 million in Q3 2023, compared to $19.3 million in Q2 2023 and $19.0 million in Q1 2023.